Verve Therapeutics Inc (NASDAQ: VERV) kicked off on Tuesday, down -2.13% from the previous trading day, before settling in for the closing price of $7.98. Over the past 52 weeks, VERV has traded in a range of $4.30-$19.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 126.44% over the last five years. While this was happening, its average annual earnings per share was recorded 22.10%. With a float of $63.10 million, this company’s outstanding shares have now reached $84.64 million.
The firm has a total of 255 workers. Let’s measure their productivity. In terms of profitability, gross margin is 73.07%, operating margin of -928.6%, and the pretax margin is -806.35%.
Verve Therapeutics Inc (VERV) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 25.47%, while institutional ownership is 74.24%. The most recent insider transaction that took place on Dec 02 ’24, was worth 3,130. In this transaction Chief Financial Officer of this company sold 555 shares at a rate of $5.64, taking the stock ownership to the 5,380 shares. Before that another transaction happened on May 14 ’24, when Company’s insider bought 76,000 for $6.26, making the entire transaction worth $475,760. This insider now owns 342,509 shares in total.
Verve Therapeutics Inc (VERV) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.28% during the next five years compared to -67.06% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Take a look at Verve Therapeutics Inc’s (VERV) current performance indicators. Last quarter, stock had a quick ratio of 13.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.81 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Analysing the last 5-days average volume posted by the [Verve Therapeutics Inc, VERV], we can find that recorded value of 1.37 million was lower than the volume posted last year of 1.66 million. As of the previous 9 days, the stock’s Stochastic %D was 56.77%. Additionally, its Average True Range was 0.61.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 78.18%, which indicates a significant increase from 47.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.25% in the past 14 days, which was lower than the 92.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.57, while its 200-day Moving Average is $5.88. Now, the first resistance to watch is $8.00. This is followed by the second major resistance level at $8.19. The third major resistance level sits at $8.38. If the price goes on to break the first support level at $7.62, it is likely to go to the next support level at $7.43. Now, if the price goes above the second support level, the third support stands at $7.24.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
The company with the Market Capitalisation of 661.23 million has total of 84,664K Shares Outstanding. Its annual sales at the moment are 11,760 K in contrast with the sum of -200,070 K annual income. Company’s last quarter sales were recorded 6,870 K and last quarter income was -50,130 K.
